Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>PegBio raised HKD 300.8m (USD 38m) from its global offering and will list on the Hong Kong Stock Exchange on Tuesday, May 27th.</li>
<li>In our previous note, we looked at the company's GLP-1 product and its valuation.</li>
<li>In this note, we provide an update for the IPO before trading debut. The free float shares are mostly at the hands of retail investors.</li>
</ul>


PegBio raised HKD 300.8m (USD 38m) from its global offering and will list on the Hong Kong Stock Exchange on Tuesday, May 27th.
In our previous note, we looked at the company's GLP-1 product and its valuation.
In this note, we provide an update for the IPO before trading debut. The free float shares are mostly at the hands of retail investors.


<ul>
<li>PegBio, a China-based near commercial stage biotech company, launched its IPO to raise up to US$39m via a Hong Kong listing.</li>
<li>We have previously covered the company's fundamentals and valuation. We highlight issues of the company.</li>
<li>In this note, we look at the deal term. We think the valuation is demanding, but the company managed to get support from local government facilitate its listing.</li>
</ul>


PegBio, a China-based near commercial stage biotech company, launched its IPO to raise up to US$39m via a Hong Kong listing.
We have previously covered the company's fundamentals and valuation. We highlight issues of the company.
In this note, we look at the deal term. We think the valuation is demanding, but the company managed to get support from local government facilitate its listing.


PegBio 派格生物 IPO: A Hardsell but Mostly Done Deal

<ul>
<li>PegBio is looking at raising up to USD 100m to list in Hong Kong.</li>
<li>We have previously covered the company’s fundamentals and a brief valuation.</li>
<li>We also took a look at changes to its prospectus. The company filed an updated version. We are taking a close look.</li>
</ul>


PegBio is looking at raising up to USD 100m to list in Hong Kong.
We have previously covered the company’s fundamentals and a brief valuation.
We also took a look at changes to its prospectus. The company filed an updated version. We are taking a close look.


PegBio 派格生物 Pre-IPO: R&D Deceleration

<ul>
<li>PegBio is looking at raising up to USD 100m to list in Hong Kong.</li>
<li>We have previously covered the company’s fundamentals and a brief valuation.</li>
<li>We look at the difference between previous filing and current PHIP filing. We see massive delays which don’t position the company well for the listing.</li>
</ul>


PegBio is looking at raising up to USD 100m to list in Hong Kong.
We have previously covered the company’s fundamentals and a brief valuation.
We look at the difference between previous filing and current PHIP filing. We see massive delays which don’t position the company well for the listing.


PegBio 派格生物 IPO: PHIP Updates Don’t Look Good

<ul>
<li>PegBio, a China-based biotech company, plans to raise up to USD 150 million via a Hong Kong listing.</li>
<li>In our previous note, we examined the company’s core product namely PB-119.</li>
<li>In this note, we will provide a valuation for the company’s key products.</li>
</ul>


PegBio, a China-based biotech company, plans to raise up to USD 150 million via a Hong Kong listing.
In our previous note, we examined the company’s core product namely PB-119.
In this note, we will provide a valuation for the company’s key products.


PegBio (派格生物) IPO: Thoughts on Valuation

China

PegBio Co., Ltd. conducts biotechnology businesses. The Company develops innovative treatments for chronic diseases and metabolic diseases. PegBio provides its services throughout Japan.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

PegBio (2565 HK)

PegBio IPO Trading Update

PegBio raises $38m in global offering, set to list on HK Stock Exchange with retail investors holding majority of free float shares.

Ke Yan, CFA, FRM

PegBio 派格生物 IPO: A Hardsell but Mostly Done Deal

China-based biotech company PegBio launches IPO in Hong Kong to raise up to US$39m, with demanding valuation but support from local government for...

Ke Yan, CFA, FRM

PegBio 派格生物 Pre-IPO: R&D Deceleration

PegBio plans to raise up to $100m for a Hong Kong listing. We examined its latest prospectus and noted besides massive delays spotted in last PHIP...

Ke Yan, CFA, FRM

PegBio 派格生物 IPO: PHIP Updates Don’t Look Good

PegBio plans to raise up to $100m for a Hong Kong listing. We compared the filings and noted massive delays and more competitors joining the race.

Ke Yan, CFA, FRM

PegBio (派格生物) IPO: Thoughts on Valuation

China's PegBio seeks to raise $150 million through Hong Kong listing. In this note, we provide an valuation framework for its key product PB-119.

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

PegBio IPO Trading Update

​PegBio raises $38m in global offering, set to list on HK Stock Exchange with retail investors holding majority of free float shares.

Ke Yan, CFA, FRM

PegBio 派格生物 IPO: A Hardsell but Mostly Done Deal

​China-based biotech company PegBio launches IPO in Hong Kong to raise up to US$39m, with demanding valuation but support from local government for...

Ke Yan, CFA, FRM

PegBio 派格生物 Pre-IPO: R&D Deceleration

​PegBio plans to raise up to $100m for a Hong Kong listing. We examined its latest prospectus and noted besides massive delays spotted in last PHIP...

Ke Yan, CFA, FRM

PegBio 派格生物 IPO: PHIP Updates Don’t Look Good

​PegBio plans to raise up to $100m for a Hong Kong listing. We compared the filings and noted massive delays and more competitors joining the race.

Ke Yan, CFA, FRM

PegBio (派格生物) IPO: Thoughts on Valuation

​China's PegBio seeks to raise $150 million through Hong Kong listing. In this note, we provide an valuation framework for its key product PB-119.

Ke Yan, CFA, FRM

PegBio raises $38m in global offering, set to list on HK Stock Exchange with retail investors holding majority of free float shares.

China-based biotech company PegBio launches IPO in Hong Kong to raise up to US$39m, with demanding valuation but support from local government for...

PegBio plans to raise up to $100m for a Hong Kong listing. We examined its latest prospectus and noted besides massive delays spotted in last PHIP...

PegBio plans to raise up to $100m for a Hong Kong listing. We compared the filings and noted massive delays and more competitors joining the race.

China's PegBio seeks to raise $150 million through Hong Kong listing. In this note, we provide an valuation framework for its key product PB-119.